Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
NCT04023396Phase 2Completed
- Sponsor
- Abivax
- Start
- Jan 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of obefazimod in ulcerative colitis (UC), sponsored by Abivax. Started Jan 2020; status: completed.
02
Drugs
obefazimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04023396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04023396.